These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31745219)

  • 1. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
    Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
    Sci Rep; 2019 Nov; 9(1):17086. PubMed ID: 31745219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
    Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
    Mitran B; Thisgaard H; Rosenström U; Dam JH; Larhed M; Tolmachev V; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():6873684. PubMed ID: 29097932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
    Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
    Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
    Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
    Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
    PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
    Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
    Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
    Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
    Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative PET imaging study of
    Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
    Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
    Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
    Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Novel [
    Kanellopoulos P; Bezverkhniaia E; Abouzayed A; Rosenström U; Tolmachev V; Orlova A
    ACS Omega; 2024 Apr; 9(16):18608-18616. PubMed ID: 38680331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
    Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
    Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR
    Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
    Abouzayed A; Kanellopoulos P; Gorislav A; Tolmachev V; Maina T; Nock BA; Orlova A
    Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.